Clinical Report: A Comprehensive Review of Strategies for Eradicating Helicobacter pylori
Overview
This review summarizes current evidence on Helicobacter pylori eradication strategies, highlighting the challenges posed by antibiotic resistance and the effectiveness of various treatment regimens.
Background
Helicobacter pylori is a prevalent chronic infection linked to significant gastrointestinal diseases, including peptic ulcers and gastric cancer. The rising rates of antibiotic resistance complicate treatment efforts, necessitating updated strategies for effective eradication.
Data Highlights
Over half of the global population is infected with H. pylori, with clarithromycin resistance exceeding 15%-20% in many regions. Current first-line treatments, such as bismuth quadruple and concomitant regimens, achieve eradication rates above 85% in high-resistance areas.
Key Findings
H. pylori infection is prevalent in over 4 billion people globally, particularly in Africa, South America, and Asia.
Clarithromycin resistance is a significant barrier to effective treatment, with rates exceeding 15%-20% in many regions.
Bismuth quadruple and concomitant regimens are recommended as first-line treatments in areas with high resistance.
Adjunctive therapies, including probiotics and N-acetylcysteine, can enhance eradication rates and treatment tolerability.
Clinical Implications
Clinicians should consider regional resistance patterns when selecting H. pylori treatment regimens.
Conclusion
Eradicating H. pylori is vital for preventing gastric cancer.
